Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial


Carpentier P., van Bellen B., Karetova D., Hanafiah H., Enriquez-Vega E., Kirienko A., ...More

INTERNATIONAL ANGIOLOGY, vol.36, no.5, pp.402-409, 2017 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 36 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.23736/s0392-9590.17.03801-9
  • Journal Name: INTERNATIONAL ANGIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.402-409
  • Istanbul University Affiliated: No

Abstract

BACKGROUND: Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF.